Britain and America have concluded a important bilateral deal that will guarantee no tariffs on British medicine exports going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise spending on drugs through the public health system. This move secures that tariffs on these key exports will stay at zero for a timeframe of three years.
This deal follows recent threats to significantly raise duties on branded pharmaceutical products, with potential rates discussed reaching one hundred percent.
"This arrangement between the UK reinforces the global environment for innovative medicines and introduces much-needed fairness to transatlantic medicine commerce," an announcement noted.
Commercial Significance
Drugs are one of the UK's biggest exports to the United States, which is easily the primary market for major companies like GSK and AstraZeneca.
Trade data reveal that in the year leading up to last September, the UK exported medicines totaling £11.1bn to the US. This value made up a significant portion of total UK exports in that span.
"This agreement safeguards jobs, boosts investment and sets the stage for the UK to emerge as a international leader for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The pact includes several specific pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must refund to the NHS to control costs will be restricted at 15%. In the past, repayments topped twenty percent.
Broader Context
The pact takes place against a long-running dispute between the drug companies and the ministers over spending levels and approval rates.
These tensions were intensified by assertions that US consumers were charged several times more for the identical medicines than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial expansions have been announced toward American operations.
A senior figure stated that the NHS had to increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its total funding over the last ten years.
